Drug
Motixafortide clinical trials
Also written BL-8040, APHEXDA™ and BKT140.
- studies test it
- 19
- open now
- 3
- in phase 3
- 2
- first study started
- 2008
Keep track of what changes. Save the motixafortide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
19 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 13
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 10
BioLineRx, Ltd. (5) · Washington University School of Medicine (5) · Hoffmann-La Roche (2) · Columbia University (1) · M.D. Anderson Cancer Center (1) · Biokine Therapeutics Ltd (1) · Guangzhou Gloria Biosciences Co., Ltd. (1) · St. Jude Children's Research Hospital (1)
Often tested with
Tested in the same studies.
Atezolizumab (3) · Gemcitabine (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Cobimetinib (2) · Tiragolumab (2) · Granulocyte Colony-Stimulating Factor (2) · Filgrastim (2)
Studies
Open first, then newest update. How each study uses motixafortide is read from its arms, and is right about nine times in ten.
Testing it · 19
- Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsRecruitingPhase 3Guangzhou Gloria Biosciences Co., Ltd.NCT06514508Written as Motixafortide+G-CSF
- SCD Stem Cell Mobilization and Apheresis Using MotixafortideRecruitingPhase 1St. Jude Children's Research HospitalNCT06442761Written as Motixafortide
- Motixafortide for MRD Sensitization in AMLRecruitingPhase 2Washington University School of MedicineNCT07392970Written as Motixafortide
- Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic AdenocarcinomaActive, not recruitingPhase 2Columbia UniversityNCT04543071Written as Motixafortide
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03281369Written as BL-8040
- A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)Active, not recruitingPhase 3BioLineRx, Ltd.NCT03246529Written as BL-8040 1.25 mg/kg + G-CSF
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedPhase 1/2Hoffmann-La RocheNCT03193190Written as BL-8040
- A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF MobilizationCompletedPhase 1Washington University School of MedicineNCT06547112Written as Motixafortide
- Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)CompletedPhase 1Washington University School of MedicineNCT05618301Written as Motixafortide
- Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT02907099Written as CXCR4 Antagonist BL-8040
- Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML PatientsCompletedPhase 2BioLineRx, Ltd.NCT01838395Written as BL-8040
- Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)TerminatedPhase 1/2BioLineRx, Ltd.NCT03154827Written as BL-8040
- Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedPhase 2Washington University School of MedicineNCT02639559Written as BL-8040
- BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic LymphomaTerminatedPhase 2Washington University School of MedicineNCT02763384Written as BL-8040
- Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic SyndromeCompletedPhase 2BioLineRx, Ltd.NCT02462252Written as BL-8040
- Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous LeukemiaWithdrawnPhase 1/2Sheba Medical CenterNCT02115672Written as BL-8040
- BL-8040 Addition to Consolidation Therapy in AML PatientsStatus unknownPhase 2Dr. Petra TschanterNCT02502968Written as BL-8040
- A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy VolunteersCompletedPhase 1BioLineRx, Ltd.NCT02073019Written as BL-8040
- Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma PatientsCompletedPhase 1/2Biokine Therapeutics LtdNCT01010880Written as BKT140
Given in every arm · 3 — motixafortide is usual care beside what is tested
- Gene Editing For Sickle Cell DiseaseRecruitingPhase 1St. Jude Children's Research HospitalNCT06506461Written as Motixafortide
- Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE TrialRecruitingPhase 4Emory UniversityNCT07101445Written as Motixafortide
- Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer PatientsCompletedPhase 2BioLineRx, Ltd.NCT02826486Written as BL-8040
Codes
What other systems call motixafortide · ClinicalTrials.gg INT004125
- MeSH (NLM) C116977motixafortideOne source NLM
- UNII (FDA) DA9G065962MOTIXAFORTIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27276305motixafortideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88309MotixafortideOne source FDA
- DrugBank DB14939One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C116977 | motixafortide | One source NLM |
| UNII (FDA) | DA9G065962 | MOTIXAFORTIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27276305 | motixafortide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88309 | Motixafortide | One source FDA |
| DrugBank | DB14939 | — | One source Wikidata |
Also registered as motixafortide acetate (UNII 3ZPX60DV8A).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.